The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions Is BPC 157 Legal? Understanding Its Status and Implications In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for The Peptide Split: How GLP 1s, Lutathera, Vosoritide, and Peptide Cancer Vaccines Are Quietly Rewriting Medicine While BPC 157, TB 500, MOTS c, and the Wellness Grift Borrow Their Halo FDA Peptide Reclassification 2026: What It Means for Providers